THIS ARTICLE IS MORE THAN FIVE YEARS OLD
This article is more than five years old. Autism research — and science in general — is constantly evolving, so older articles may contain information or theories that have been reevaluated since their original publication date.
President Donald Trump’s pick to lead the U.S. Food and Drug Administration (FDA) has deep ties to the pharmaceutical industry as a consultant, investor and board member. Nominee 
Scott Gottlieb also has worn many hats in a career that includes two previous stints at the FDA, practicing as a physician, and writer and editor roles at prestigious medical journals.
“It seems like the main question is, ‘Which Gottlieb are we going to get?’” says Robert Califf, who stepped down from his position as commissioner of the FDA in January.
Here’s a look at Gottlieb’s career, by the numbers:
188 companies:
New Enterprise Associates, the venture capital firm where Gottlieb is a partner, is currently or has been invested in 188 healthcare companies.
8 boards of directors:
Gottlieb serves or served on eight boards of directors, according to his LinkedIn profile. The firms include pharmaceutical companies Gradalis and Tolero Pharmaceuticals, which are developing cancer treatments, among other things; and Glytec, which offers glycemic management tools for people with diabetes.
8 drug and device companies:
Eight pharmaceutical companies disclosed payments to Gottlieb in 2015, according to the open payments database: Vertex Pharmaceuticals, GlaxoSmithKline, Daiichi, Valeant, Pfizer, Millennium, SI-BONE and E.R. Squibb & Sons. Payments included travel to Philadelphia, San Francisco and London.
9 recusals:
In a memo, Gottlieb wrote that he had a consulting relationship with nine healthcare companies before his stint as the FDA’s deputy commissioner for medical and scientific affairs during the George W. Bush administration. Those ties disqualified him from dealing with matters concerning those companies for at least a year. The firms included Eli Lilly, Roche and Sanofi-Aventis.
The recusals generated some headlines during the avian flu scare because Gottlieb had to recuse himself from some of the planning efforts around vaccines.
7 years:
Starting in 1997, Gottlieb spent seven years as a staff writer for the British Medical Journal, one of the top medical journals in the world. And he was an editor at the Pulse section of the Journal of the American Medical Association from 1996 to 2001.
Gottlieb also spent the past seven years as an adviser to drugmaker GlaxoSmithKline’s product investment board, according to his LinkedIn page.
33 years old:
Gottlieb was 33 when he got the No. 2 job at the FDA in 2005. He had done a short stint at the agency a few years earlier, but was considered a controversial pick because of his ties to Wall Street. He stayed until 2007.
“He has done a lot of thinking about how FDA should be managed — his operational sophistication is going to be a great asset,” says former FDA attorney Coleen Klasmeier, who worked with Gottlieb and co-authored articles with him. “He also has very strong relationships among career FDA personnel and will be able to hit the ground running on a range of important initiatives.”
18 times before Congress:
Gottlieb testified before Congress as an expert witness 18 times. He has spoken about drug prices, revamping the FDA approval process and the vaccine supply.
“Most people watching at the FDA would breathe a sigh of relief,” Joshua Sharfstein, who served as the FDA’s principal deputy commissioner until 2011, says of Gottlieb’s impending nomination. He adds that Gottlieb is “not someone who has expressed antagonism to the core principles of the agency.”
36,000 Twitter followers:
More than 36,000 people follow Gottlieb on Twitter, though he follows only 845 people, as of 14 March. He has tweeted at least 10,400 times, lately about different strains of the flu.
72 percent:
Almost three-fourths of the 53 drug companies surveyed by Mizuho say they’d prefer Gottlieb to head the FDA.
$414,000:
Pharmaceutical companies paid Gottlieb nearly $414,000 from 2013 through 2015, according to federal open payments data, for speeches, consulting, travel and meals.
That includes $65,780 from a pharmaceutical company to promote a controversial cystic fibrosis drug called Kalydeco. Only one other doctor received more money toward promoting the drug.
The drug’s price tag was controversial because the nonprofit Cystic Fibrosis Foundation kicked in $150 million toward finding a cure for the fatal disease and got a rich $3.3 billion payday for selling its rights to royalties for the drug. Vertex Pharmaceuticals priced Kalydeco at more than $300,000 a year.
Nearly $30,000:
Gottlieb has contributed nearly $30,000 toward Republican political campaigns and joint fundraising committees from 2005 to 2014. He has donated toward the presidential runs of Mitt Romney and Senator John McCain. He also donated more than once to U.S. House of Representatives Speaker Paul Ryan.
Gottlieb contributed the most money toward Republican Senator Ben Sasse of Nebraska, spending $2,600 in the primary and $2,600 again in the general election in 2013. Sasse was vocally anti-Trump, penning an open letter in February 2016 about how he could not support Trump, who was “dividing” the nation, in his view.
“But have you noticed how Mr. Trump uses the word ‘Reign’ — like he thinks he’s running for King?” Sasse asked in the post.
This story originally appeared on Kaiser Health News. It has been slightly modified to reflect Spectrum’s style.
By joining the discussion, you agree to our privacy policy.